The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
| Autor: | Horwitz, S., O'Connor, O.A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N.L., Christensen, J.H., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W.S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S.-P., Shustov, A., Hüttmann, A., Savage, K.J., Yuen, S., Zinzani, P.L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M., Illidge, T. |
|---|---|
| Zdroj: | In Annals of Oncology March 2022 33(3):288-298 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|